Biotechnology company Valneva (VALN.US) has released new data on its Chikungunya virus vaccine, which could potentially be used for adolescents.

Valneva (VALN.US), a French biotechnology company, has released additional data on its FDA-approved Chikungunya virus vaccine Ixchiq from a Phase 3 trial in Brazil involving 12-17-year-olds.

Following the data release, Valneva traded 8.70% higher premarket to $4.75.

The company reported that new data from its VLA1553-321 trial showed a 98.3% seroconversion rate in trial participants who were Chikungunya virus negative at baseline one year after a single Ixchiq injection.

By comparison, the seroconversion rates were 99.1% at six months and 98.8% at 28 days post-vaccination. Valneva added that the safety data from the study involving 754 participants confirmed the previously determined Ixchiq tolerability profile.

Chikungunya fever is a mosquito-borne viral disease that the World Health Organization has classified as a major public health problem. The US FDA approved Ixchiq as the world's first Chikungunya fever vaccine in November last year.

The company released 28-day and six-month data from the VLA1553-321 trial in 2023 and 2024, respectively. The findings support Ixchiq's label expansion applications in the US, Europe and Canada, targeting adolescents.